The ^99mTc-IgG complex enables detection and localization of inflammatory foci of various etiology, with high sensitivity and specificity with respect to a reference method using labelled granulocytes.
^99mTc-ECD (^99mTc-N,N’-1,2-ethylenediylbis-L-cysteine diethyl ester) is a radiopharmaceutical effectively crossing the blood-brain barrier and is retained specificaly in the brain. Like the ^99mTc-HMPAO complex, it can be used for scintigraphic evaluation of cerebral blood flow.
The paper estimates the risk related to application of both the compounds, by calculating the average organ dose delivered per unit administered activity and the resulting effective dose. The knowledge of the kinetics of their retention and excretion from the body was based on extrapolation of data obtained from controlled animal study.
The estimated values of the effective dose per unit injected activity are:
E = 0.010 mSv/1 MBq - for 99mTc-IgG compound and
E = 0.005 mSv/1 MBq - for 99mTc-ECD compound,
and the risk of undesired stochastic effects related with diagnostic procedures employing the new compounds, being of the order = 10^-5, seems to be acceptable in oncological diagnostics.